The following is a summary of “Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes,” published in the May 2025 issue of Frontiers in Endocrinology by Colletta et al.
The post Kidney and Liver Effects of SGLT2i in Cirrhosis first appeared on Physician’s Weekly.
